TY - JOUR
T1 - Myostatin and other musculoskeletal markers in lung transplant recipients
AU - Kerschan-Schindl, Katharina
AU - Ebenbichler, Gerold
AU - Gruther, Wolfgang
AU - Föger-Samwald, Ursula
AU - Kudlacek, Stefan
AU - Patsch, Janina
AU - Gleiss, Andreas
AU - Jaksch, Peter
AU - Klepetko, Walter
AU - Pietschmann, Peter
N1 - Publisher Copyright:
© 2018, The Author(s).
PY - 2019/2/1
Y1 - 2019/2/1
N2 - Recipients of lung transplantation (LuTx) may experience impaired muscle function and bone metabolism even after rehabilitation. We investigated the potential use of musculoskeletal markers in identifying the impairment of muscle function and bone function in these patients. Biochemical parameters, bodily functions, and lung function of 37 LuTx recipients were evaluated at the time of their discharge from the hospital stay and about 6 months later. The biomarkers were also assessed in 30 healthy age and gender distribution-matched controls. Compared to controls, the negative muscle regulator myostatin was elevated in LuTx recipients at baseline and follow-up, whereas its opponent follistatin only showed a group-specific difference at follow-up. LuTx recipients had reduced serum levels of sclerostin and increased levels of dickkopf 1 and periostin. Lung function and physical function were improved during follow-up. The change in lung function was correlated with the change in chair-rising time and the 6-min walking test. At follow-up, all musculoskeletal markers of LuTx recipients differed from those of controls, thus reflecting their still reduced lung function and bodily functions. Among the tested biomarkers, myostatin, sclerostin, dickkopf 1, and periostin were useful to detect impaired musculoskeletal function in LuTx recipients. Myostatin may serve as a target of treatment in the future.
AB - Recipients of lung transplantation (LuTx) may experience impaired muscle function and bone metabolism even after rehabilitation. We investigated the potential use of musculoskeletal markers in identifying the impairment of muscle function and bone function in these patients. Biochemical parameters, bodily functions, and lung function of 37 LuTx recipients were evaluated at the time of their discharge from the hospital stay and about 6 months later. The biomarkers were also assessed in 30 healthy age and gender distribution-matched controls. Compared to controls, the negative muscle regulator myostatin was elevated in LuTx recipients at baseline and follow-up, whereas its opponent follistatin only showed a group-specific difference at follow-up. LuTx recipients had reduced serum levels of sclerostin and increased levels of dickkopf 1 and periostin. Lung function and physical function were improved during follow-up. The change in lung function was correlated with the change in chair-rising time and the 6-min walking test. At follow-up, all musculoskeletal markers of LuTx recipients differed from those of controls, thus reflecting their still reduced lung function and bodily functions. Among the tested biomarkers, myostatin, sclerostin, dickkopf 1, and periostin were useful to detect impaired musculoskeletal function in LuTx recipients. Myostatin may serve as a target of treatment in the future.
KW - Adaptor Proteins, Signal Transducing
KW - Adolescent
KW - Adult
KW - Aged
KW - Aged, 80 and over
KW - Biomarkers/blood
KW - Bone Morphogenetic Proteins/blood
KW - Cell Adhesion Molecules/blood
KW - Female
KW - Follistatin/blood
KW - Genetic Markers
KW - Humans
KW - Intercellular Signaling Peptides and Proteins/blood
KW - Lung Transplantation
KW - Male
KW - Middle Aged
KW - Musculoskeletal Diseases/pathology
KW - Myostatin/blood
KW - Prospective Studies
KW - Respiratory Function Tests
KW - Transplant Recipients
KW - Young Adult
UR - http://www.scopus.com/inward/record.url?scp=85061831625&partnerID=8YFLogxK
U2 - 10.1007/s10238-018-0532-3
DO - 10.1007/s10238-018-0532-3
M3 - Journal article
C2 - 30317402
SN - 1591-8890
VL - 19
SP - 77
EP - 85
JO - Clinical and Experimental Medicine
JF - Clinical and Experimental Medicine
IS - 1
ER -